The liver is a fat-rich organ that deals with many problematic substances with high energy consumption. These three circumstances suggest the use of tocotrienolsn for the liver - as an extremely good and fat-soluble antioxidant. This was also confirmed early on by studies on NAFLD (non-acloholic fatty liver disease).
Some studies:
December 2013: 87 people with NAFLD (detected on ultrasound) received either 200mg of mixed tocotrienols or placebo in this randomized study for a year. In the end there was a significant improvement in liver values. In the placebo group subjects two suffered a deterioration in the period, in the T3 group no. Link to study:tocotrienolsfor normalization of hepatic echogenic response in nonalcoholic fatty liver: a randomized placebo-controlled clinical trial
November 2013: 81 patients on hemodialysis received either mixed tocotrienols (TRF, 180 mg tocotrienols, 40 mg tocopherols) or placebo. After 12 or 16 weeks, the TRF group showed better lipid values. Link to study:Vitamin EtocotrienolSupplementation improves lipid profiles in chronic hemodialysis patients
February 2012: The Wexner Medical Centre at the Ohio State University notes a slowing of progression in patients with advanced liver injury. It is suggested that patients who are waiting for a liver transplant can be given longer time from death by giving tocotrienol and the quality of life can be improved. From the text:Oral administration of tocotrienol also lowered the model for end stage liver disease (MELD) score in 50 percent of the patients who received TE supplements, while only 20 percent of patients who received TCP supplements experienced a reduction in their MELD score. MELD score refers to a clinical scoring system used to determine the severity of chronic liver disease and assess the priority and need for liver transplant allocation.
The original text the study:Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients.
